Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. - Sarkozy C; Chartier L; Ribrag V; Gressin R; Geisler CH; Kluin-Nelemans HC; Thieblemont C; Morschhauser F; Lemonnier F; Safar V; Tessoulin B; Oberic L; et al. (Blood cancer journal, 2025)